MSB 7.69% $1.19 mesoblast limited

Novartis deal on the rocks, page-126

  1. 15,454 Posts.
    lightbulb Created with Sketch. 5535
    We get your theory @Davisite after saying basically the same thing 10+ times already today but it is just that - your theory ..... unless of course you are one of these doctors you are talking about and undertook such observations and discussions yourself ?

    I think another thing you are forgetting is how 'under the pump these doctors are' ... some of the videos I have seen they can barely drive themselves home after a double shift .... I doubt they are spending all this extra time cross referencing information and having meetings with other doctors to discuss their theories and perform statistically analysis on their patients etc

    .... and making comments like this is misleading

    https://hotcopper.com.au/threads/an...824426/page-825?post_id=49711831#.X97ildgzbIU

    Right now the only data that MSB has on ARDS is that they don’t work

    You, like the rest of us, have no way of knowing whether Remestemcel-L works or not on COVID-19 ARDS or non COVID-19 ARDS patients; certain cohorts etc etc - it's all conjecture until the data is unblinded .... just sayin'
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.